Arrayit Corporation (ARYC)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Arrayit Corporation (ARYC) with AI Score 58/100 (Hold). Arrayit Corporation develops and markets life science tools and integrated systems for genetic analysis and diagnostics. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Arrayit Corporation (ARYC) Healthcare & Pipeline Overview
Arrayit Corporation develops, manufactures, and markets life science tools and integrated systems for genetic variation analysis and diagnostics. The company's microarray technology and instruments serve genomic research centers, pharmaceutical companies, and academic institutions. With a focus on early disease detection, Arrayit operates in the competitive medical diagnostics and research sector.
Investment Thesis
Arrayit Corporation operates in the medical diagnostics and research sector, focusing on microarray technology. The company's gross margin of 49.4% indicates potential profitability in its core operations. However, the negative profit margin of -231.4% raises concerns about overall financial health. Key growth catalysts include expanding the application of its microarray technology in early disease detection and increasing sales of automated microarray instruments. Potential risks include the company's small market capitalization of $0.00B and high beta of -15.67, indicating high volatility. Investors should carefully consider the financial metrics and market position before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross margin of 49.4% suggests potential efficiency in Arrayit's core microarray technology business.
- Negative profit margin of -231.4% raises concerns about the company's overall financial health and expense management.
- Market capitalization of $0.00B indicates the company is a micro-cap stock with associated volatility and liquidity risks.
- Beta of -15.67 suggests the stock price moves inversely and with greater magnitude than the market, indicating high volatility.
- Arrayit serves genomic research centers, pharmaceutical companies, and academic institutions, indicating a diversified customer base within the life sciences sector.
Strengths
- Proprietary microarray printing technology
- Integrated systems for genetic variation analysis
- Established relationships with research institutions
- Specialized expertise in microarray applications
Weaknesses
- Negative profit margin
- Small market capitalization
- High beta indicating high volatility
- Limited financial resources
Catalysts
- Ongoing: Expansion of microarray applications in early disease detection.
- Ongoing: Increasing sales of automated microarray instruments.
- Ongoing: Development and marketing of consumables for microarray technology.
- Ongoing: Entering strategic partnerships with pharmaceutical companies.
- Ongoing: Expanding into international markets.
Risks
- Potential: Competition from larger companies with greater resources.
- Potential: Regulatory changes affecting the medical diagnostics industry.
- Potential: Technological advancements rendering current products obsolete.
- Potential: Economic downturns impacting research funding.
- Ongoing: Negative profit margin and limited financial resources.
Growth Opportunities
- Expanding Microarray Applications in Early Disease Detection: Arrayit can capitalize on the growing demand for early disease detection by developing and marketing diagnostic microarrays for various treatable disease states. The market for early disease diagnostics is projected to reach billions of dollars by 2030, driven by advancements in genomics and proteomics. Arrayit's microarray technology offers a platform for high-throughput screening and personalized medicine, providing a competitive advantage in this expanding market. Timeline: Ongoing.
- Increasing Sales of Automated Microarray Instruments: Arrayit can increase revenue by expanding the sales of its automated microarray manufacturing instruments, such as NanoPrint and SpotBot Titan, to research institutions and pharmaceutical companies. The market for automated laboratory equipment is expected to grow, driven by the need for increased efficiency and throughput in research and development. Arrayit's instruments offer customizable solutions for microarray manufacturing, catering to the specific needs of its customers. Timeline: Ongoing.
- Developing and Marketing Consumables for Microarray Technology: Arrayit can leverage its existing customer base by developing and marketing consumables, such as glass substrates, reagents, and clean room supplies, for microarray technology. The market for laboratory consumables is stable and recurring, providing a consistent revenue stream for the company. By offering high-quality consumables specifically designed for its instruments, Arrayit can enhance customer loyalty and increase market share. Timeline: Ongoing.
- Entering Strategic Partnerships with Pharmaceutical Companies: Arrayit can accelerate its growth by entering strategic partnerships with pharmaceutical companies to develop and commercialize diagnostic microarrays and tools for specific disease areas. Collaborating with established pharmaceutical companies can provide access to funding, expertise, and distribution channels, enabling Arrayit to expand its market reach and product portfolio. These partnerships can focus on developing personalized medicine solutions and companion diagnostics. Timeline: Ongoing.
- Expanding into International Markets: Arrayit can expand its geographic reach by targeting international markets, particularly in Asia and Europe, where there is growing demand for life science tools and diagnostic technologies. Entering new markets requires adapting products and services to local regulatory requirements and customer needs. By establishing partnerships with local distributors and research institutions, Arrayit can effectively penetrate these markets and increase its global presence. Timeline: Ongoing.
Opportunities
- Expanding microarray applications in early disease detection
- Increasing sales of automated microarray instruments
- Developing and marketing consumables
- Entering strategic partnerships with pharmaceutical companies
Threats
- Competition from larger companies
- Regulatory changes
- Technological advancements
- Economic downturns
Competitive Advantages
- Proprietary microarray printing technology.
- Integrated systems for genetic variation analysis.
- Established relationships with research institutions and pharmaceutical companies.
- Specialized expertise in microarray technology and applications.
About ARYC
Arrayit Corporation, founded to advance life science research and diagnostics, develops, manufactures, and markets tools and integrated systems for analyzing genetic variation and biological function. The company's core business revolves around microarray technology, which enables the analysis of DNA, protein, antibody, lipid, and carbohydrate microarrays for applications such as gene expression, genotyping, and protein profiling. Arrayit offers a range of automated microarray manufacturing instruments, including the NanoPrint, SpotBot Titan, and SpotLight CCD fluorescence scanners. These instruments cater to various research and diagnostic needs, providing solutions for high-throughput sample processing and analysis. In addition to instruments, Arrayit manufactures consumables like glass substrates, reagents, and clean room supplies. The company serves genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies worldwide. Headquartered in Sunnyvale, California, Arrayit Corporation continues to focus on developing innovative tools for early disease detection and advancing life science research.
What They Do
- Develops microarray tools and components.
- Manufactures life science tools and integrated systems.
- Markets life science tools and integrated systems.
- Offers custom printing and analysis of microarrays for research.
- Identifies and develops diagnostic microarrays for early disease detection.
- Provides automated microarray manufacturing instruments.
Business Model
- Sales of microarray tools and components to research institutions and pharmaceutical companies.
- Custom printing and analysis of microarrays for research purposes.
- Development and sales of diagnostic microarrays for early disease detection.
- Manufacturing and sales of automated microarray manufacturing instruments.
Industry Context
Arrayit Corporation operates within the medical diagnostics and research industry, a sector characterized by rapid technological advancements and increasing demand for personalized medicine. The market for microarray technology is driven by the need for high-throughput analysis of genetic variation and biological function. Arrayit competes with companies offering similar tools and services, including those specializing in genomics, proteomics, and diagnostics. The industry is subject to regulatory requirements and intellectual property protection, influencing the competitive landscape and market access.
Key Customers
- Genomic research centers
- Pharmaceutical companies
- Academic institutions
- Clinical research organizations
- Government agencies
- Biotechnology companies
Financials
Chart & Info
Arrayit Corporation (ARYC) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ARYC.
Price Targets
Wall Street price target analysis for ARYC.
MoonshotScore
What does this score mean?
The MoonshotScore rates ARYC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Rene A. Schena
Managing
Rene A. Schena is the managing person at Arrayit Corporation, overseeing the company's operations and strategic direction. Information about his detailed career history, education, and previous roles is not available in the provided data. He is responsible for leading the company's efforts in developing, manufacturing, and marketing life science tools and integrated systems.
Track Record: Due to limited information, Rene A. Schena's specific achievements, strategic decisions, and company milestones under his leadership cannot be comprehensively assessed. However, as the managing person, he is responsible for guiding the company's activities in the competitive life sciences technology sector and managing its seven employees.
ARYC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Arrayit Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries higher risks compared to stocks listed on major exchanges like NYSE or NASDAQ due to the lack of stringent listing requirements and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or mismanagement
- Lack of regulatory oversight
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any legal or regulatory issues.
- Monitor news and press releases for any updates or developments.
- Consult with a financial advisor before investing.
- Development of microarray tools and components.
- Manufacturing of life science tools and integrated systems.
- Marketing of life science tools and integrated systems.
What Investors Ask About Arrayit Corporation (ARYC)
What does Arrayit Corporation do?
Arrayit Corporation develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation, biological function, and diagnostics. The company's core offerings include microarray printing technology, automated microarray manufacturing instruments, and related consumables. Arrayit serves genomic research centers, pharmaceutical companies, academic institutions, and other organizations involved in life science research and diagnostics, providing tools for gene expression analysis, genotyping, and protein profiling.
What do analysts say about ARYC stock?
There is currently no available analyst coverage or consensus on Arrayit Corporation (ARYC) due to its OTC listing and small market capitalization. Investors should conduct their own thorough research and due diligence before considering an investment in ARYC. Key valuation metrics, such as price-to-earnings ratio and price-to-sales ratio, may not be readily available or reliable due to limited financial disclosure and trading activity.
What are the main risks for ARYC?
The main risks for Arrayit Corporation include its negative profit margin, small market capitalization, and high beta, indicating high volatility. As an OTC-listed company, ARYC faces additional risks related to limited financial disclosure, low trading volume, and potential for price manipulation. Competition from larger companies with greater resources and regulatory changes in the medical diagnostics industry also pose significant challenges. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for ARYC?
Arrayit Corporation (ARYC) currently holds an AI score of 58/100, indicating moderate score. Key strength: Proprietary microarray printing technology. Primary risk to monitor: Potential: Competition from larger companies with greater resources.. This is not financial advice.
How frequently does ARYC data refresh on this page?
ARYC prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ARYC's recent stock price performance?
Recent price movement in Arrayit Corporation (ARYC) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary microarray printing technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ARYC overvalued or undervalued right now?
Determining whether Arrayit Corporation (ARYC) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ARYC?
Before investing in Arrayit Corporation (ARYC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be limited due to OTC listing.
- AI analysis pending for ARYC.